Bayer stock dips despite analyst support and Amundi stake disclosure

Published on 09/18/2026 at 14:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock trades around 48.6 euros on Xetra on September 18, 2026, about 9 percent below its 52-week high after a strong year-to-date run. Analyst targets up to 70 euros and a new Amundi voting-rights notification shape the current risk-reward picture.

Forscherin im weißen Kittel pipettiert an einem beleuchteten Laborarbeitsplatz vor einem Bildschirm mit 3D-Molekülstruktur — Pharmazeutisches Forschungslabor – Wissenschaftlerin mit Pipette, Molekülstruktur-Monitor, blaue LED-Beleuchtung, Illustration mit AI erstellt.

Bayer AG (ISIN DE000BAY0017) stock is trading at about 48.57 euros on Xetra on September 18, 2026, roughly 9.9 percent below its 52-week high after a strong recovery over the past year.

Amundi stake move and FDA news frame sentiment

According to Financial Times, Bayer disclosed a voting rights notification under the German Securities Trading Act showing that Amundi S.A. crossed a major shareholding threshold with an event date of September 14, 2026 and publication on September 18, 2026.

A report from Goldesel highlights that Amundi exceeded the 3 percent voting-rights threshold and that Bayer also received a US approval for its kidney drug Kerendia, adding a regulatory tailwind to the equity story as of September 18, 2026.

Price performance and volatility in focus

Per data cited by Investing.com, Bayer stock is quoted at 48.57 euros on Xetra on September 18, 2026, compared with a previous close of 49.04 euros, implying an intraday decline of about 0.96 percent.

The same overview from Investing.com shows a 52-week trading range between 25.78 euros and 53.92 euros, so the current price stands about 88.2 percent above the 52-week low and 9.9 percent below the high, underlining how far the shares have rebounded from last year’s trough.

In a separate feature on options pricing, Saxo notes on September 18, 2026 that Bayer’s implied volatility stands at 36.47 percent against historical volatility of 17.52 percent, indicating that options are currently pricing roughly twice the movement the shares have recently delivered.

Analyst targets underline upside potential

An analysis on Stock-World reports that Barclays raised its price target for Bayer from 60 euros to 70 euros on September 8, 2026 while maintaining an Overweight rating, positioning the new target about 44.2 percent above the current Xetra price of 48.57 euros.

The same article from Stock-World states that Deutsche Bank Research reaffirmed its Buy recommendation with a 60-euro price target on September 9, 2026, which still implies about 23.5 percent upside versus the latest Xetra quote.

According to Stock-World, Bayer stock closed at 49.17 euros on Xetra on September 17, 2026, a rise of 0.7 percent versus the prior day, and has gained about 78 percent over the past twelve months and 33 percent year-to-date, while remaining 8.7 percent below a 52-week high of 53.86 euros reached in early July 2026.

Long-term performance and market value

A retrospective calculation by finanzen.ch on September 18, 2026 shows that an investment of 1,000 euros in Bayer shares ten years ago would have been worth about 548.94 euros at a closing price of 49.04 euros on September 17, 2026, corresponding to a historical loss of 45.11 percent over the decade.

The same finanzen.ch piece indicates that Bayer’s market capitalization recently stood at about 48.12 billion euros as of mid September 2026, underlining that despite long-term share price damage the company remains one of the larger constituents of Germany’s DAX 40 index.

Recent trading dynamics

A same-day market update from finanzen.ch notes that Bayer shares were down about 0.6 percent at 48.74 euros on Xetra around 9:28 a.m. on September 18, 2026, after opening at 49.05 euros and touching an intraday low of 48.53 euros.

In a corporate-news overview on September 18, 2026, Ad-hoc corporate news reports that Bayer stock closed at 48.98 euros on Xetra on September 16, 2026, marking a daily gain of 0.55 percent on trading volume of 1,359,264 shares, which points to solid liquidity in the stock.

Closing price snapshot and investor takeaway

Based on the latest available Xetra data, Bayer stock is trading at 48.57 euros on September 18, 2026, compared with a previous close of 49.04 euros, leaving the shares about 9.9 percent below the 52-week high of 53.92 euros and well above the 52-week low of 25.78 euros.